Category Archives: stocks to avoid

Posted on by

The Oracle in the AI coal mine?

Over the last months, I have written two Weeklies, criticizing the from my view not sustainable AI investment frenzy, featuring Meta’s stock as my main target. Maybe this was because Meta is a mainstream darling that on top has delivered a stellar return over the last three years. However, little did I know that there is an even more interesting case in the second row. With some interesting developments in the recent past, is this the Oracle in the AI coal mine for what to expect?

Continue reading →
Posted on by

Don’t skip this: Why I‘ve been (+ remain) negative on consumer stocks

I must admit I am surprised how angry people can become when their widows and orphans stocks, mainly consumer staples with reliable dividends, are attacked. It is no secret that I‘ve been writing and commenting negatively about them for some time. And I was right in most cases, as these “safe bets“, which according to the fan base belong in every defensive portfolio, have performed very poorly. I stick to my view that the dividends won’t be safe over time. Once and for all, I am now unveiling why my pessimism likely is warranted.

Continue reading →
Posted on by

Meta going all in – More cracks in the AI Capex bubble

In August 2025, I published my first Weekly fully dedicated to this topic. It became my second most read Weekly so far. I gave it the name “Artificial Intelligence meets natural stupidity – and a potential winner no one is counting on”. I introduced my readers to the growing Capex mania of the Big Tech companies, focussing on Meta, and concluding that Apple might turn out to be the winner thanks to avoiding doing stupid things. While the mania continues at even more extreme levels, the risks for a big burst have only increased.

Continue reading →
Posted on by

Side Effect of AI: The Storage Bubble + New Research Report

It is no secret that AI as a topic, its various applications, and in consequence stocks related to AI are receiving much attention. More and more challenge the sustainability of this rapid rise over the last few years, especially as the question of profitability remains unanswered. While everyone is aware of stocks like Nvidia, Oracle or critical suppliers like Micron, as well as multiple AI chatbots, the AI mania has pulled up an otherwise boring sub-segment: storage stocks. Is this justified? All my paid-members receive my latest stock idea: a growing franchise that’s set to dominate the eye care market.

Continue reading →
Posted on by

Nomad Foods: Tasty Deal?

In the spotlight today is the Western European market leader in the frozen food industry. With a portfolio of multiple brands, the company’s roots span over a century. The current setup was formed in 2015, when the brands Iglo and Findus were acquired. Since the IPO, a decade has passed, yet the stock is trading (again) where it had started. Are a near 5% dividend yield and a PE ratio of 7 enough to spark appetite, or is something fishy?

Continue reading →
Posted on by

Diageo – Does Johnnie keep on stumblin’?

Though initially not planned as a trilogy in that sense, today I am taking a closer look at Diageo, the world’s biggest spirits company. Like its competitors Pernod Ricard and Brown-Foreman, Diageo stock has nosedived, and caused strong headaches for its investors. After the stock got cut in half, while the broader market ran from high to high, the question arises, whether this could be a good contrarian pick right now. Especially with the dividend now being on a historically high level.

Continue reading →
Posted on by

(Un)Safety first: The Drama of Sarepta Therapeutics

Biotech stocks are known for two things: either being graveyards for shareholders’ money or generating outsized returns – especially if they become multi-baggers (assuming one is positioned before the retail crowd discovers such ideas). While not every biotech stock turns out to be a do-or-die binary bet, it is safe to say that those stocks with big moves catch much attention – no matter the direction. Sarepta Therapeutics is such a case. It has even offered its shareholders both, an astronomical rise and a fall from grace despite generating billion-USD sales. A case study worth to have heard of.

Continue reading →
Posted on by

PVH Corp.: Trading at 6x earnings – still not a buy

While it likely makes sense to be cautious when a stock trades at a high valuation multiple, the case of PVH Corp. might raise some eyebrows – at least at first sight. The company owns two well-known apparel brands, has been constantly profitable, is generating healthy free cash flow and even buying back its own shares aggressively at a low valuation, seemingly generating strong shareholder value. Shares, however, only trade at a 6x price to earnings ratio. I’ll tell you while this likely is still not a bargain.

Continue reading →
Posted on by

4 prestigious giants set to slash their dividends

Here we go again with one of my favorite contrarian topics: Buckle up, the dividend butcher is sharpening his axe once more! Four prestigious dividend stocks once deemed safe havens are poised to slash their generosity to ribbons. With worsening fundamentals, overstretched balance sheets and drying cash flows in a challenging environment, these firms will likely need to trim the fat from their dividends in the not-too-distant future.

Continue reading →
Posted on by

PepsiCo – refreshing buy or just a crushed can?

The stock of soft drinks and snacks giant PepsiCo over the last five years has done exactly nothing. Dividends were the only form of returns, but this will hardly make investors high-five this market-lagging performance. With a just raised-again dividend, a yield on the high-end of the historical range, a comparatively low PE ratio of 16x and an uncertain economic environment, this consumer staple company might qualify for a defensive portfolio.

Continue reading →